Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (1272)	6/28/2000 10:07:00 PM
From: scaram(o)uche	Respond to of 52153

>> BTW, if MLNM is merge father I will not mind. Otherwise, I may lost another 5% hair. << Chuckle. Saw somewhere that BMY has a gamma secretase inhibitor in phase I. Arrrrrrrrrrrrrrrgggggggggggghhhhhhhhhhhhh............ A really good, classy and handsome scientist told me that it's easy to circumvent some of the SNAP claim language.

To: Miljenko Zuanic who wrote (1272)	6/28/2000 10:42:00 PM
From: Biotech Jim	Read Replies (1) \| Respond to of 52153

<<Saw somewhere that BMY has a gamma secretase inhibitor in phase I.>> This seems to be from the SIBIA collaboration, which was originally viewed as a beta secretase program. I guess that is what may happen if one uses whole cell based assays in which the PS1 is expressed. I guess they are now Merck Research Laboratories in San Diego. Impressive paper from Jules Schaeffer at MRK on the characterization of the PS1 as the aspartyl protease gamma secretase. I hear via the grapevine that getting such inhibitors inside cells is not really an issue. The real issue will be in clearing long term tox. After all, one wants to treat these patients for a long time. Another question is when to start treatment. Another question is related to the validity of the beta amyloid hypothesis. Another question is ... What a tough disease. BJ